Veru (VERU)
(Real Time Quote from BATS)
$1.01 USD
+0.04 (4.51%)
Updated May 31, 2024 03:44 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
Veru Inc. [VERU]
Reports for Purchase
Showing records 81 - 92 ( 92 total )
Company: Veru Inc.
Industry: Cosmetics
Preclinical Data in Four Types of Cancers to Be Presented at ASCO 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
FY2018 2Q Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Tamsulosin DRS NDA Filing Fee Waived; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
$10M Non-Dilutive Financing Secured; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
FY2018 1Q Financial Results Reported; NDA Filing On Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Large Public Sector FC2 Orders Expected in 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
FY2017 4Q and Full-Year Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Delayed Release Solifenacin for Overactive Bladder In-licensed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Tamsulosin DRS Demonstrates AUC Equivalence; NDA Filing in 1H 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Preboost Co-Promotion Agreement and FC2 Telemedicine Access; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
FY2017 3Q Financial Results Reported; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Veru Inc.
Industry: Cosmetics
FY2017 3Q Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.